Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
We send one confirmation email first. Only emails about NEUP, unsubscribe in one click. Privacy
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.
NEUP holds $19.9M in cash and short-term investments (as of Jun 30, 2026) and burns about $1.1M/quarter from operations, an estimated runway of 56.2 months at that rate (BioRadar estimate, not company guidance).
Dilution pressure: 25 · Moderate
Recent financing filings on SEC EDGAR:
Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when NEUP files for a raise →
| Holder | Type | Shares | % of shares | As of |
|---|---|---|---|---|
| Spyros Papapetropoulos President and CEO, Director · +113,617 options |
Insider | 5,999,940 | 110.88% | 2024-07-01 |
| Lynx1 Capital Management LP 10% owner |
Insider | 875,328 | 16.18% | 2025-12-26 |
| AdvisorShares Trust | Institution (13G, 5%+) | 312,895 | 5.78% | 2026-09-30 |
| Peter Miles Winston Davies Director · +15,320 options |
Insider | 269,984 | 4.99% | 2024-07-01 |
| David Ian Wilson Director · +15,412 options |
Insider | 251,939 | 4.66% | 2024-07-01 |
| Alan Fisher Director · +30,731 options |
Insider | 100,000 | 1.85% | 2024-07-01 |
Share count 5,411,334 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for NEUP and every other ticker you follow. Card required, cancel anytime.
Start 7-day free trial →